Wei Lin
Equibles does not estimate personal net worth.
About Wei Lin
Wei Lin has spoken on 2 earnings calls and 1 other investor event across 1 company, most recently for Revolution Medicines, Inc. on August 5, 2026. The companies whose calls Wei Lin spoke on are classified in the Healthcare sector.
Wei Lin on recent calls
“It is a very important question that we have given a lot of thought and planning to because we want to ensure the success of the 303 trial in frontline PDAV while we're trying to making sure patients globally have access to drug class.”
“RASLUTE 302 is a global randomized open-label phase 3 study that enrolled patients with previously treated metastatic PDAC. Patients were randomized one-to-one to receive either directional acid 300 milligrams orally once daily or investigate a choice of standard care chemotherapy.”
“And so the trial, as we pointed out, has been initiated, and that's the APEX study. It's a study that involves O3, and they're on RAS that covers O-RAS, the GCOD, as well.”
Affiliation history
-
Revolution Medicines, Inc. (RVMD)
Proxy statement
Start not stated–2025-04-29
Last confirmed by a filing; no departure on record